Gene · 116444
GRIN3B: glutamate ionotropic receptor NMDA type subunit 3B
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. GRIN3B: glutamate ionotropic receptor NMDA type subunit 3B. Genes, record 116444. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/116444
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| O60391 | Glutamate receptor ionotropic, NMDA 3B | 1,043 | 0 | Ensembl, GeneID, HGNC |
Source UniProt
Patents19
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4650780 A2 | 2025-11-19 | 886 | O60391 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 624 | O60391 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 1880 | O60391 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 1880 | O60391 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 624 | O60391 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 886 | O60391 | Espacenet |
| EP 4551941 A2 | 2025-05-14 | 26 | O60391 | Espacenet |
| KR 1020250036291 A | 2025-03-14 | 1 | O60391 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 35069 | O60391 | Espacenet |
| US 11400116 B2 | 2022-08-02 | 5769 | O60391 | Espacenet |
1 to 10 of 19
See all 19 patentsDrugs28
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ACAMPROSATE | CHEMBL1201293 | Glutamate [NMDA] receptor antagonist | ANTAGONIST | ChEMBL |
| ACAMPROSATE CALCIUM | CHEMBL2068724 | Glutamate [NMDA] receptor antagonist | ANTAGONIST | ChEMBL |
| AMANTADINE | CHEMBL660 | Glutamate [NMDA] receptor antagonist | ANTAGONIST | ChEMBL |
| AMANTADINE HYDROCHLORIDE | CHEMBL1569 | Glutamate [NMDA] receptor antagonist | ANTAGONIST | ChEMBL |
| APIMOSTINEL | CHEMBL3989872 | Glutamate [NMDA] receptor partial agonist | PARTIAL AGONIST | ChEMBL |
| AV-101 | CHEMBL3545351 | Glutamate [NMDA] receptor antagonist | ANTAGONIST | ChEMBL |
| AZD8108 | CHEMBL3707355 | Glutamate [NMDA] receptor antagonist | ANTAGONIST | ChEMBL |
| CNS-5161 | CHEMBL41306 | Glutamate [NMDA] receptor blocker | BLOCKER | ChEMBL |
| DELUCEMINE | CHEMBL2110814 | Glutamate [NMDA] receptor antagonist | ANTAGONIST | ChEMBL |
| ESKETAMINE | CHEMBL395091 | Glutamate [NMDA] receptor negative allosteric modulator | NEGATIVE ALLOSTERIC MODULATOR | ChEMBL |
1 to 10 of 28
See all 28 drugsTrials838
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07603596 | ESKETAMINE | PHASE1 | ClinicalTrials.gov | |
| NCT07602153 | ESKETAMINE | ClinicalTrials.gov | ||
| NCT07597486 | ESKETAMINE | ClinicalTrials.gov | ||
| NCT07584902 | ESKETAMINE | ClinicalTrials.gov | ||
| NCT07573969 | KETAMINE | PHASE3 | ClinicalTrials.gov | |
| NCT07569198 | KETAMINE | PHASE2 | ClinicalTrials.gov | |
| NCT07564531 | KETAMINE | ClinicalTrials.gov | ||
| NCT07563296 | KETAMINE | PHASE2 | ClinicalTrials.gov | |
| NCT07560878 | MEMANTINE | EARLY_PHASE1 | ClinicalTrials.gov | |
| NCT07560722 | ESKETAMINE | ClinicalTrials.gov |
1 to 10 of 838
See all 838 trialsNIH grants562
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | GRIN3B papers | Newest fiscal year |
|---|---|---|---|
| R28AA012725 | Brain Tissue Resource Center for Alcohol Research | 5 | 2025 |
| ZIAMH002857 | Glutamatergic Modulators for Rapid and Sustained Antidepressant Effect | 5 | 2025 |
| R01HD082373 | NMDAR Mutations & Neurodevelopmental Disorder: from Mechanism to Targeted Therapy | 4 | 2025 |
| R35NS111619 | Glutamate receptors and human neurological disease | 4 | 2025 |
| U24AG021886 | National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD) | 4 | 2025 |
| ZIAMH002927 | Neurobiology and Target Validation of Novel Therapeutic Agents in Mood Disorders | 4 | 2025 |
| R01NS097536 | Structural and functional investigation of allosteric NMDA receptor modulation | 3 | 2025 |
| ZIAAA000301 | Integrative genetics of behavior with high throughput technologies | 3 | 2025 |
| P01AG019724 | Frontotemporal Dementia: Genes, Images, and Emotions | 2 | 2025 |
| P01AG026276 | Antecedent Biomarkers for Alzheimer Disease: The Adult Children Study | 2 | 2025 |
1 to 10 of 562Source NIH's project files
See all 562 nih grantsPapers512
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Paradoxical Expression of Ionotropic Glutamate Receptors in Leucocytes. | Clin Rev Allergy Immunol | 2026 | 41854785 | PubTator, text mining | PubMed |
| UCM-A86 is a selective positive allosteric modulator of GluN1/GluN3 NMDA receptors. | Mol Pharmacol | 2026 | 41740201 | PubTator, text mining | PubMed |
| A subunit-selective negative allosteric modulator of GluN1/GluN3A glycine-activated receptor. | Mol Pharmacol | 2026 | 41713186 | PubTator, text mining | PubMed |
| NLRP3-mediated neuroinflammation in the ventrolateral orbital cortex contributes to the formation of morphine-induced addiction memory by upregulating GRIN3B. | Prog Neurobiol | 2026 | 41401853 | PubTator, text mining | PubMed |
| Emerging Roles of GluN3B NMDA Receptor Subunit in the Central Nervous System. | Neurosci Bull | 2026 | 41139355 | PubTator, text mining | PubMed |
| Prioritizing missense mutations via a deep learning phosphorylation prediction model. | Hum Genomics | 2025 | 41469746 | PubTator, text mining | PubMed |
| UCM-A86 is a selective positive allosteric modulator of GluN1/GluN3 NMDA receptors. | bioRxiv | 2025 | 41292873 | PubTator, text mining | PubMed |
| Trisomy 21 Disrupts Thyroid Hormones Signaling During Human iPSC-Derived Neural Differentiation In Vitro. | Cells | 2025 | 41002374 | PubTator, text mining | PubMed |
| Osteopontin derived from hypoxia-induced M2 macrophages promotes osteosarcoma progression through modulation of EGR3/ISG15 signaling and RIG-I expression. | J Transl Med | 2025 | 40841904 | PubTator, text mining | PubMed |
| Genome-Wide Association Study and Rare Variant Association Studies of Strabismus in the All of Us Research Program. | Ophthalmol Sci | 2025 | 40837069 | PubTator, text mining | PubMed |
1 to 10 of 512
See all 512 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/116444
GET https://conductscience.org/api/genes/v1/116444/patents